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Idiopathic pulmonary fibrosis has been associated with emphysema in cigarette smokers as
a new clinical entity: combined pulmonary fibrosis and emphysema (CPFE).
In order to compare histomorphometrical, roentgenological and immunohistochemical
aspects of usual interstitial pneumonia (UIP) with and without associated pulmonary emphy-
sema, 17 patients with biopsy-proven UIP were evaluated. Morphometrical evaluation of lung
parenchyma destruction was used to divide patients in two subgroups: emphysema/UIP (nZ 9)
and UIP alone (nZ 8); four patients with biopsy-proven emphysema without fibrosis were also
evaluated.
At HRTC scan, emphysematous lesions were prevalent in the upper fields of both emphy-
sema/UIP and emphysema groups and the distribution of fibrotic lesions was similar in emphy-
sema/UIP compared to UIP alone. The semiquantitative histopathological fibrotic score was
also similar in emphysema/UIP and UIP alone. In addition, the expression of tumor necrosis
factor (TNF)-a, matrix metalloproteinase (MMP)-2, MMP-9, MMP-7 and membrane type 1-
metalloproteinase (MT1-MMP) by fibroblasts of myofibroblastic foci was similar in emphy-
sema/UIP and UIP alone patients. In contrast, fibroblasts in areas of parenchymal destruction
of emphysema/UIP expressed MMP-2, MMP-9, MMP-7 and MT1-MMP at variable but significantlynatomia Patologica, Policlinico Tor Vergata, Viale Oxford 81, 00133, Rome, Italy. Tel./fax: þ39 06
.it (A. Orlandi).
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1754 P. Rogliani et al.higher levels when compared to emphysema subjects, in the presence of similar levels of TIMP-
1, TIMP-2 and TNF-a.
Fibrotic and emphysematous lesions in emphysema/UIP patients appear to follow the roent-
genological and histopathological patterns expected for either UIP or emphysema. Interstitial
fibroblast activation is more pronounced in the areas of lung destruction in emphysema/UIP
compared to those with emphysema alone, as for exaggerated tissue remodeling.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Idiopathic pulmonary fibrosis (IPF) is a lung disorder var-
iably associated with cigarette smoking whereby about half
of the subjects characterized by the pathological pattern of
usual interstitial pneumonia (UIP)1 are reported as smokers
or former smokers.2 Emphysema is the most common
cigarette smoke-related disorder.3 It has been defined as an
abnormal, permanent enlargement of airspaces distal to
the terminal bronchiole without obvious fibrosis,4 however,
the work of Thurlbeck and colleagues has suggested that
both destruction and repair abnormalities may take place
concomitantly in the emphysematous lung,5 as smoker’s
irregular enlargement of airspaces is accompanied not only
by loss of elastic tissue but also by collagen deposition.6 In
this regard, experimental animal studies suggest that
collagen and elastin deposition may be considered inter-
laced events in a complex process leading to emphysema
and to fibrosis,7,8 i.e., diseases characterized by a profound
disturbance of the lung architecture due to aberrant
destruction and/or remodeling of the extracellular matrix
(ECM). Matrix metalloproteases (MMPs) are known to play
a central role in remodeling both through ECM cleavage and
by generating bioactive mediators. Among them, MMP-2,
MMP-7 and MMP-9 are highly expressed in IPF which are
found in the alveolar and basal bronchiolar epithelial cells
and the fibroblastic foci.9 In emphysema, the expression of
MMP2, MMP9 and membrane type 1-MMP (MT1-MMP) has
been observed in epithelial cells, fibroblasts, and alveolar
macrophages, and they are thought to play a role in the
rupture of the elastic fibers.10e12 MMPs may therefore be
important both in IPF and in emphysema, thus in IPF and
emphysema combined.
Earlier clinico-roentgenological and experimental
studies of pulmonary fibrosis associated with emphysema
have described pulmonary fibrosis as a ‘‘second disease’’,
superimposed upon pre-existing emphysema.13 More
recently, Cottin and co-workers have described a rather
large series of patients with a variety of fibrotic disorders
associated with emphysema, thereby identifying a new
disease entity called ‘‘combined pulmonary fibrosis and
emphysema’’ (CPFE), an entity which can be recognized at
computerized tomography.14
Since no correlative analysis of the roentgenological,
histomorphometrical and immunohistochemical features of
combined fibrosis and emphysema has been reported so far,
this study was undertaken to immunohistochemically
characterize the presentation of IPF associated with
emphysema in order to correlate histo- and HRCT-mor-
phometrical findings with immunohistochemical data in an
attempt to investigate whether the concomitant pulmonaryfibrosis may modify the destruction and remodeling
patterns of associated pulmonary emphysema.
Methods and materials
Study population
Seventeen patients with IPF were included in the study. All
met the ATS/ERS Consensus criteria for the diagnosis of IPF2
as they had an HRCT scan consistent with the IPF pattern of
pulmonary fibrosis (honeycombing with basal and periph-
eral reticular opacities and traction bronchiectasis, in the
absence of peribronchovascular nodules, micronodules,
isolated cysts and consolidation) and a histological pattern
typical of UIP on lung biopsy obtained by video-assisted
thoracoscopy. The initial evaluation included detailed
history, including occupational activity, physical examina-
tion, chest X-rays and routine blood tests. Serum anti-
neutrophil cytoplasmic antibody (P-ANCA), C-ANCA,
extractable nuclear antigens (ENA), antinuclear, anti-
mitochondrial and anti-DNA antibodies, rheumatoid factor,
angiotensin converting enzyme and cryoglobulins were
analyzed in order to rule out the diagnosis of collagen
vascular diseases. Four patients presented mildly increased
levels of anti-DNA antibodies.
The study was approved by the Institutial Bioethics
Committee of the University of Roma ‘‘Tor Vergata’’.
Histomorphometrical analysis
Tissue sections were stained with HaematoxylineEosin
(Fig. 1A) and Masson’s trichrome stains, and analyzed by
two independent observers blind of the patient diagnosis.
Fibrosis was scored by measuring the percentage of tissue
with fibrotic changes on Masson’s trichrome stained
sections at 250 magnifications and graded as follows:
0 (<25%); 1 (25e50%), 2 (50e75%); 3 (75e100%). Fibrosis
was calculated in at least 10 randomly selected fields for
each case; the number of fields to obtain a significant
difference was calculated according to stereological
formulae, as previously reported.15 The parenchymal
destruction index, expressed as the percentage of the
pulmonary surface showing septal disruption, was micro-
scopically evaluated using morphometric methods with
computer-assisted image analysis, using Scion Image Soft-
ware on HaematoxylineEosin stained sections at 250
magnifications captured by a Hamamatsu camera (Hama-
matsu City, Japan) connected to a Nikon microscope
(Tokyo, Japan), as previously described.15,16 At least 10
randomly selected fields were measured for each case and
the number of fields to obtain a significant difference was
Figure 1 (A) HaematoxylineEosin stained section of an emphysema/UIP patient’s lung parenchyma, showing emphysematous
areas adjacent to regions more closely resembling classic UIP at low magnification. (B) Masson’s trichrome stain of a classic
fibroblastic focus in fibrotic area of emphysema/UIP lung parenchyma fibrotic area. Original magnifications, AZ20, BZ250.
HRCT and histomorphometry in combined UIP/emphysema 1755calculated according to stereological formulae.15 The mean
value of parenchymal destruction index calculated in all IPF
cases was 39.8, thus the value of 40 was chosen to
discriminate the emphysema/UIP group from the UIP alone
group.
Histomorphometrically defined study subgroups
After histopathological quantification of pulmonary emphy-
sema, subjects with parenchymal destruction index greater
than 40 were categorized as combined emphysema/UIP
(nZ 9) and those with less than 40 as UIP alone (nZ 8). The
emphysema/UIP group comprised three females and six
males. They were all former smokers. Seven of them had
been treated with corticosteroids, one with azathioprine
and one with interferon-gamma. The UIP alone group
included three females and five males. Five of them were
current/former smokers and three never smoked. Six of
them had been treated with corticosteroids. Four subjects
with typical pulmonary emphysema were included in the
study as disease controls. All had lung tissue examination as
for lung cancer resection. They included one female and
three males and all of them were former smokers.
High-resolution computerized tomography
(HRCT) scanning
Chest radiographs and HRTC scans were reviewed by an
experienced thoracic radiologist unaware of patients’
clinical details. HRCT images were scored for fibrosis and
emphysema separately, using three sections taken at the
level of the aortic arch (upper fields), the carina (medium
fields) and 1 cm above the diaphragm (lower fields), as
described by Kazerooni et al.17 Each field was scored for
fibrosis taking into account the following variables: ground-
glass attenuation, interstitial thickening, subpleural cysts
and generalized intraparenchymal cysts. Emphysema was
defined as permeative destruction, without visible walls
and without uniform distribution.4 Bullae were defined as
confluent areas of low density, arranged on a single layer,
with a diameter of at least 1 cm, with a convex outline, thin
walls and absence of lung tissue within the bulla.18 The
percentage of the lung involvement for each type of finding
(ground glass, interstitial thickening, subpleural cysts,generalized cysts, emphysema and bullae) was assessed
visually and classified on a five point scale as 0 (absent),
1 (<25% of area involved), 2 (25e50% involved), 3 (50e75%
involved), and 4 (>75% involved).
Pulmonary function tests
Lung function testing included dynamic and static lung
volumes (Master lab Jaeger, Wu¨rzburg, Germany) and
arterial blood gas analysis. The normal spirometric values
from the European Coal and Steel Community were used as
reference.19
Immunohistochemistry
The protein expression of MMP-2, MMP-9, MMP-7 and MT1-
MMP of the tissue inhibitors of metalloproteinases (TIMP)
TIMP-1 and TIMP-2 and of tumor necrosis factor-a (TNF-a)
was investigated using immunohistochemistry; 4 mm thick
serial sections fromeach patient’ lung biopsywere placed on
Superfrost Plus slides (Menzel-Glaser, Braunschweig, Ger-
many) and baked overnight at 60 C. After deparaffinization in
xylene and rehydration in graded concentrations of ethanol,
sectionswere incubated in 0.3%hydrogen-peroxideemethanol
to block endogenous peroxidases and rinsed with PBS.
Non-specific antibody binding was blocked by incubation
with normal goat serum (Ylem, Avezzano, Italy; 1:20 in
BSA 5%) for 30 min at room temperature. Antibody dilutions
were 1:100 for mouse monoclonal antibodies anti-MT1-MMP
(Oncogene, San Diego, CA), MMP-2 (Calbiochem, Cambridge,
MA), MMP-7 (kindly provided by Prof. M. Chilosi, Verona,
Italy), and rabbit polyclonal anti-MMP-9 (Neomarkers, Fre-
mont, CA, USA), 1:10 for mouse monoclonal antibodies anti-
TIMP-1 and TIMP-2 (Calbiochem, Cambridge, CA) and 1:100
for goat polyclonal anti-TNF-a (Santa Cruz Biotechnology
Inc., Santa Cruz, CA) and all antibodies were incubated for
30 min. Sections were then incubated with specific Biotin-
labelled secondary antibodies, followed by a streptavidine
horseradish peroxidases conjugate. Bound antibody was
revealed with the use of the substrate 3,30-dia-
minobenzedine. Positive (high-grade mammary carcinoma)
and negative (non-specific IgG, 5 mg/ml, instead of primary
antibody) controls were includedwith each batch of sections
to confirm the consistency of the analysis. Sections of
Table 1 Patients’ demographical and functional
characteristics
Emphysema/
UIP
UIP Emphysema
Male/female 6/3 5/3 2/2
Age 71 2.8 65 4 73 2
Smoker (ever/never) 9/0 5/3 4/0
Corticosteroid
therapy (yes/no)
6/3 6/2 0/4
FVC (% pred) 82 6 69 8 85 4
FEV1 (% pred) 83 5 71 8 58 4
FEV1/FVC 85 2 81 2 53 4
RV % (pred) 78 7 65 8 149 18
TLC (% pred) 76 6 63 6 106 7
pH 7.4 0 7.4 0.01 7.4 0.01
PaO2 (mmHg) 79 4 73 5 70 8
PaCO2 (mmHg) 41 1 37 1 47 4
1756 P. Rogliani et al.parenchyma from four non-smoking patients from lung
cancer resection (mean age 65 14.1) with no clinico-
radiological signs of emphysema were also used as negative
controls. Interstitial fibroblasts were evaluated in thickened
septa of emphysematous areas as well as in fibroblastic or
myofibroblastic foci of emphysema/UIP patients; pneumo-
cytes, macrophagic and capillary endothelial cells were
morphologically excluded; cells of uncertain categorization
areas were re-evaluated after routinary AE1/AE3 cytoker-
atin, CD68 and Factor VIII immunostaining of serial sections
(Diapath-Ventana system, Tucson, AZ, USA). Immunostaining
was graded as follows: 0 (complete absence of or weak
staining in <10% of cells); 1 (weak staining in <50% or
strong staining in <10% of cells); 2 (weak staining in >50%
or strong staining in <50% of cells); 3 (strong staining in
>50% cells). Semiquantitative analysis was carried out by
two observers without knowledge of the patient clinico-
roentgenological status or of the antibody examined. For
each case, at least 10 randomly selected high power fields
were evaluated, as previously reported.20
Statistical analysis
Clinic-radiological values are presented as mean S.E.M.
Distribution analysis was performed with the Kolmogorove
Smirnov test with the DallaleWilkinson approximation to
Lilliefor’s method for all variables. For multiple comparison
among groups (functional, radiographical and histopatho-
logical variables) either one-way ANOVA followed by Tukey’s
test, or Kruskal-Wallis and Dunns tests, when appropriate,
were used. Histomorphometrical and immunohistochemical
results were analysed by Student’s t test and expressed as
arbitrary unitsþ S.E.M. P values less than 0.05were regarded
as significant. Statistical analysis was performed with
GraphPad Prism 4 (GraphPad Software, San Diego, CA).Results
Pulmonary function testing
Among the nine subjects with emphysema/UIP, four showed
normal lung volumes while five had mildly reduced lung
volumes; airflow was preserved in all subjects. Mild
hypoxemia was present in four (Table 1). Among the eight
patients with UIP alone, six presented mildly/moderately
reduced lung volumes, one had very mildly reduced airflow
(p> 0.19 all comparisons, emphysema/UIP vs. UIP alone
group, Table 1) and five showed mild hypoxemia (p> 0.79
all comparisons, emphysema/UIP vs. UIP alone group,
Table 1). All the four emphysema subjects had increased
lung volumes (pZ 0.024 for RV and pZ 0.017 for TLC
compared to the emphysema/UIP group; Table 1) with
impaired airflow (pZ 0.001 compared to the emphysema/
UIP group, Table 1) and mild to moderate hypoxemia
(pZ 0.51 compared to the emphysema/UIP group, Table 1).
HRCT evaluation
Fibrotic abnormalilties were mainly represented by inter-
stitial thickening and both subpleural and generalized cystsin the emphysema/UIP as well as in the UIP alone subjects.
In both groups, ground glass was modest in all lung fields.
The distribution of fibrotic lesions in the upper, middle and
lower fields of the lungs was not significantly different in
the emphysema/UIP compared to the UIP alone group
subjects (p> 0.07, all comparisons; Fig. 1B,D,F). HRCT non-
bullous emphysematous abnormalities were seen in six out
of the nine subjects in the emphysema/UIP group but in
none of the UIP alone group. HRCT bullous emphysematous
abnormalities were present in two subjects in the emphy-
sema/UIP group. One of the subjects assigned to the latter
group did not show any HRCT bullous or non-bullous
abnormalities. In this group, emphysematous lesions were
prevalent in the upper fields, although the difference was
not statistically significant (Fig. 2A,C,E; pZ 0.45 upperþ
medium fields vs. lower fields). In the subjects with
emphysema alone, there was a trend toward upper lobes
predominance of HRCT non-bullous emphysematous
abnormalities (pZ 0.14 upperþmedium fields vs. lower
fields) and no HRCT fibrotic lesions were seen.
Morphometry and immunohistochemistry
The fibrotic score, microscopically calculated on Masson’s
trichrome stained sections (Fig. 1B), was not different in
the emphysema/UIP and UIP groups (Table 2), while it was
significantly lower in the emphysema group (pZ 0.002), as
expected. Conversely, the parenchymal destruction index
was significantly higher in the emphysema than in the
emphysema/UIP group (pZ 0.007, Table 2). Obviously,
parenchymal destruction index was also significantly higher
in the emphysema/UIP group than in the UIP group
(pZ 0.002, Table 2).
TNF-a expression was present in macrophages and in the
epithelium of terminal bronchioles, but it was almost absent
in fibrotic areas, without differences between the UIP and
the emphysema/UIP group (0.37 0.12 and 0.44 0.13,
respectively). In the emphysema group, TNF-a expression
was almost absent (0.1 0.1).
MMPs expression was weakly positive or absent in
interstitial stromal tissue as well as in lymphocytes and
neutrophils but was present in interstitial fibroblasts and,
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Figure 2 Typical HRCT scan of an emphysema/UIP patient. (A) Fibrotic reticular lesions, prevalently subpleural, and extended
emphysema, are seen in the upper fields. (C) Carena: coarse reticular lesions with subpleural cysts, predominantly in the left lung,
and bullous emphysema at the apex of the inferior lobe and in the lingula. (E) Lower fields: coarse reticular lesions with subpleural
and intraparenchymal cysts are seen bilaterally. Distribution of fibrosis visual scores in the upper (B), medium (D) and lower (F)
fields in emphysema/UIP and UIP alone patients, respectively.
HRCT and histomorphometry in combined UIP/emphysema 1757with greater intensity, in pneumocytes. MMPs were instead
expressed at higher levels in the fibroblastic foci of both
UIP and emphysema/UIP (Fig. 3). In addition, interstitial
fibroblasts present in the areas of parenchymal destruction
in emphysema/UIP expressed MMP-2, MMP-7, MMP-9 and
MT1-MMP with higher, although variable, intensity than in
emphysema (p< 0.02, p< 0.001, p< 0.01 and p< 0.03,
respectively) (Fig. 3). The different expression of MMPs inTable 2 Radiographic and pathological findings
characteristics
Emphysema/
UIP
UIP Emphysema
Ground glass 0.3 0.1 1.0 0.4 0 0
Interstitial thickening 1.6 0.3 2.4 0.4 0 0
Subpleural cysts 1.5 0.4 1.6 0.2 0 0
Total cysts 0.9 0.3 1.3 0.3 0 0
Bullae 0.1 0.1 0.1 0.1 0 0
Emphysema 0.5 0.2 0.2 0.2 1.4 0.4
Fibrosis (%) 2.0 0.3 2.1 0.2 0.9 0.1
Parenchymal
destruction index
53.4 4.9 28.0 2.9 70.0 1.2the two groups above was observed in the presence of
similarly low levels of TIMP-1 (0.19 0.1 and 0.25 0.14;
p> 0.05) and TIMP-2 (0.37 0.12 and 0.3 0.14; p> 0.05).
In contrast to the emphysema/UIP patients, in the UIP
alone group the typical patchy areas of fibrosis and struc-
tural remodeling were alternating with apparently normal
residual parenchyma, where MMP and TIMP immunoreac-
tivities were similar to that of normal lung parenchyma of
control tissue samples (not shown).
Discussion
The combination of IPF and emphysema, which has been
recently defined by Cottin and co-workers as a new disease
entity, CPFE, recognizable at computerized tomography,14
has been described by a number of functional and radio-
graphic studies in humans,21e23 and it has been shown that
in experimental animals exposure to cadmium7 or over-
expression of TNF-a8 may lead to the development of
concomitant pulmonary fibrosis and emphysema.
With regard to human disease, Hiwatari and co-workers
described the development of fibrosis as a superimposed
co-morbidity in patients with a known history of pulmonary
emphysema,13 in the context of this observation our
Figure 3 Immunohistochemical and semiquantitative analyses of matrix metalloproteinases (MMPs) expression in lung paren-
chyma interstitial fibroblasts (AeF). Immunohistochemical investigation of lung parenchymal interstitial MT1-MMP (A, B) MMP-9
(C, D) and MMP-7 (E, F) in emphysema/UIP (A,C,E) and typical emphysema (B,D,F). (G) Bar graph showing semiquantitative analysis
that reveals interstitial fibroblasts of parenchymal destruction areas of emphysema/UIP stain more than in those of typical
emphysema subjects. (H) Bar graph of semiquantitative evaluation of MMPs expression in fibroblast foci of lung parenchyma
emphysema/UIP and UIP alone. Diaminobenzidine as chromogen; original magnification, 200.
1758 P. Rogliani et al.morphometrical and immunohistochemical studies were
undertaken to investigate whether the development of UIP
in subjects upon pre-existing emphysema might play a role
in the disease processes of CPFE.Consistent with the observation of Hunninghake and
colleagues,24 the comparison of the roentgenological
markers of fibrosis by visual quantification in emphysema/
UIP patients and patients with UIP alone did not show any
HRCT and histomorphometry in combined UIP/emphysema 1759significant difference in the type and distribution of
fibrotic lesions. In both groups, IPF-type lesions were
prevalent in the lower lobes but were also found in the
subpleural regions of the upper lobes. Furthermore, the
histopathological fibrosis scores were very similar in the
two patient groups.
With regard to emphysematous abnormalities, the
comparison of emphysema/UIP and emphysema cases
confirmed the observation of Cottin and coworkers14 that
the spatial distribution of roentgenological markers of lung
destruction was very similar in patients with emphysema or
emphysema/UIP,14,22,25 thus indicating that, as for fibrotic
lesions, the morphology of emphysema in the emphysema/
UIP subjects is similar to that of emphysema presenting
alone.
Given the longer natural history of smoker’s emphyse-
ma,26e28 it is reasonable to think that our results that IPF
may develop upon an already anatomically altered lung,13
hence one might, however, ask whether emphysematous
and fibrotic lesions will progress independently or the
development of IPF may modify the progression of
emphysema.
Two sets of disease modifying factors have been
examined in the present study: TNF-a and the MMP family
of proteases. The role of the TNF-a gene in the patho-
genesis of pulmonary fibrosis has been clearly demon-
strated in the mouse model8,29,30 and in human gene
association31,32 and cytokine expression studies.31,33 In
this study we were only able to demonstrate faint tissue
expression of TNF-a, with no differences between
macrophages or terminal bronchiole epithelial cells in
emphysema/UIP and UIP. In the context of the demon-
stration of the importance of TNF-a in the pathogenesis
of emphysema,8,34 in addition to IPF, the present obser-
vation cannot exclude a role for TNF-a in the inflamma-
tory process of emphysema or emphysema associated
with UIP.
Matrix metalloproteinases (MMPs) are a family of
structurally related enzymes that are capable of degrad-
ing all components of the extracellular matrix and base-
ment membranes. The MMP family comprises over 20
members sharing 32e49% aminoacid similarity and has
similar structural domains.35 Expression of the MMPs has
been observed in lung diseases leading to the destruction
of lung parenchyma, such as IPF9 and emphysema.36 In
experimental animal models and in human IPF, where
heightened expression of MMP-2 and MMP-9 has been
extensively described, these MMPs are thought to play
a major role in the disruption of basement membranes
and fibroblast invasion of the alveolar spaces.9 In
emphysema, upregulation of MMP-2 and MMP-9 has been
observed in epithelial cells and alveolar macrophages,
suggesting that their exaggerated expression may
contribute to interstitial fibrillar collagen degradation and
to the breakdown of elastic fibers.11 In addition, the
expression of MMP-7, that is primarily expressed by the
abnormal bronchial epithelium in UIP,9,37 as well as that of
MT1-MMP, a membrane associated protein and an acti-
vator of pro-MMP-2 that play a pivotal role in the aberrant
remodeling of the lung microenvironment and that of
TIMPs, which are expressed38,39 by epithelial cells and
activated fibroblasts in the alveolar buds and fibroblasticfoci of IPF,35,40,41 is thought to characterize the MMP
expression pattern in UIP.
In this study, MMP-2, MMP-9, MMP-7 and MT1-MMP
were found to be expressed at similar levels in the
fibroblastic foci of UIP and emphysema/UIP patients,
thus suggesting not only that the fibrotic lesions of
emphysema/UIP and UIP share similar histopatological
and roentgenological patterns, but also display similar
activation patterns of profibrotic gene.37,39 Furthermore,
this study shows that, different from the areas of unin-
volved lung parenchyma described in UIP next to the
fibroblastic foci, the areas of tissue destruction of
emphysema/UIP are characterized by the presence of
interstitial fibroblasts expressing high levels of MMP-2,
MMP-7, MMP-9 and MT1-MMP, which are not seen in
patients with emphysema, but unaffected by pulmonary
fibrosis, with no significant differences in TIMP levels. It
is thus enticing to hypothesize that increased MMPs
expression may play a role in accelerating the process of
destruction and remodeling of emphysema in these
patients with combined emphysema and IPF.6 Is the
activation of fibroblasts in the areas of tissue destruction
of emphysema/UIP indicative of a more aggressive
disease process, leading to the more precipitous course
of CPFE? It has been reported that in CPFE patients
respiratory failure occurs more rapidly and that pulmo-
nary hypertension leading to cor pulmonale is more
frequent.14 Whether the observed exaggerated activation
of mesenchymal cells affects the emphysematous process
we cannot say. A limitation of the present study is rep-
resented by the limited size of available bioptic tissue
samples, so that lung structure and biology, including
morphometrical and immunohistochemical data, in UIP
unaffected segments or lobes remain uninvestigated.
This notwithstanding, the data indicate UIP and emphy-
sema as two overlapping processes, whereby the UIP
process appears to alter both normal and the emphyse-
matous lung. In the context of the observation that all of
the emphysema/UIP patients in this and in previous
studies13,14,22,25 were smokers it is enticing to hypothe-
size that, although the role of cigarette smoking in the
pathogenesis of UIP has not been firmly established yet,
tobacco smoke is likely to play an important role in the
abnormalities characterizing parenchymal destruction in
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